Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
äŒæ¥ã³ãŒãTHRD
äŒç€ŸåThird Harmonic Bio Inc
äžå Žæ¥Sep 15, 2022
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°53
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 15
æ¬ç€Ÿæåšå°1700 Montgomery Street
éœåžSAN FRANCISCO
蚌åžååŒæNASDAQ Global Market Consolidated
åœUnited States of America
éµäŸ¿çªå·94111
é»è©±çªå·12097272457
ãŠã§ããµã€ãhttps://thirdharmonicbio.com/
äŒæ¥ã³ãŒãTHRD
äžå Žæ¥Sep 15, 2022
æé«çµå¶è²¬ä»»è
ãCEOã- -
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã